Trial Profile
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 19 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2024.
- 14 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.
- 31 Aug 2016 Status changed from suspended to active, no longer recruiting.